Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catlow

Showing results (331-340 of 363) with videos related to

Pageof 37
Sort By:
Journal of Medicinal Chemistry|May 17, 2013
Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonistsJames A Monn, Matthew J Valli, Steven M Massey, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2016
Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headacheMaria-Jesus Blanco, Dana R Benesh, James A Knobelsdorf, et al.
Neuropharmacology|January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu<sub>2/3</sub> receptor antagonistJeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.
Faraday Discussions|June 23, 2023
Homogeneous N<sub>2</sub> activation: general discussionAndrew Ashley, Katharina Brinkert, C Richard A Catlow, et al.
Physical Chemistry Chemical Physics : PCCP|April 25, 2023
Multiscale QM/MM modelling of catalytic systems with ChemShellYou Lu, Kakali Sen, Chin Yong, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of DepressionJ M Witkin, S N Mitchell, K A Wafford, et al.
Faraday Discussions|June 27, 2023
Alternative routes to NH<sub>3</sub> and its application: general discussionC Richard A Catlow, Joseph El-Kadi, Yeqin Guan, et al.
Journal of Medicinal Chemistry|August 5, 2005
Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonistAna Belén Bueno, Iván Collado, Alfonso de Dios, et al.
Faraday Discussions|June 22, 2016
Catalyst design from theory to practice: general discussionCharles Campbell, Rutger van Santen, Michail Stamatakis, et al.
Pharmacology, Biochemistry, and Behavior|March 3, 2019
The α2,3-selective potentiator of GABA<sub>A</sub> receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in ratsJ M Witkin, R Cerne, P G Davis, et al.
Pageof 37

Showing results (331-340 of 363) with videos related to

Sort By:
Pageof 37
Journal of Medicinal Chemistry|May 17, 2013
Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonistsJames A Monn, Matthew J Valli, Steven M Massey, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2016
Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headacheMaria-Jesus Blanco, Dana R Benesh, James A Knobelsdorf, et al.
Neuropharmacology|January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu<sub>2/3</sub> receptor antagonistJeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.
Faraday Discussions|June 23, 2023
Homogeneous N<sub>2</sub> activation: general discussionAndrew Ashley, Katharina Brinkert, C Richard A Catlow, et al.
Physical Chemistry Chemical Physics : PCCP|April 25, 2023
Multiscale QM/MM modelling of catalytic systems with ChemShellYou Lu, Kakali Sen, Chin Yong, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of DepressionJ M Witkin, S N Mitchell, K A Wafford, et al.
Faraday Discussions|June 27, 2023
Alternative routes to NH<sub>3</sub> and its application: general discussionC Richard A Catlow, Joseph El-Kadi, Yeqin Guan, et al.
Journal of Medicinal Chemistry|August 5, 2005
Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonistAna Belén Bueno, Iván Collado, Alfonso de Dios, et al.
Faraday Discussions|June 22, 2016
Catalyst design from theory to practice: general discussionCharles Campbell, Rutger van Santen, Michail Stamatakis, et al.
Pharmacology, Biochemistry, and Behavior|March 3, 2019
The α2,3-selective potentiator of GABA<sub>A</sub> receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in ratsJ M Witkin, R Cerne, P G Davis, et al.
Pageof 37